Tireless research reveals secrets of the 'sleep hormone'
A team from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University has made a major breakthrough by unraveling the inner workings of melatonin, also known as the "sleep hormone." The ...
Neuroscience
Dec 13, 2011 |
5 / 5 (4) |
0
|
New class of potential drugs inhibits inflammation in brain
Scientists at Emory University School of Medicine have identified a new group of compounds that may protect brain cells from inflammation linked to seizures and neurodegenerative diseases.
Neuroscience
Feb 14, 2012 |
4.5 / 5 (4) |
0
|
Avastin disappoints against ovarian cancer
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...
Cancer
Dec 28, 2011 |
4.3 / 5 (4) |
1
Heart hormone helps shape fat metabolism
It's well known that exercising reduces body weight because it draws on fat stores that muscle can burn as fuel. But a new study at Sanford-Burnham Medical Research Institute (Sanford-Burnham) suggests that ...
Medical research
Feb 06, 2012 |
5 / 5 (3) |
0
|
Ancient heart drug activates body's own protective mechanisms in blood vessels
An ancient heart drug that's inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today.
Medications
Jun 14, 2012 |
5 / 5 (3) |
0
|
Spend less on older therapies and the new ones will be more affordable
Australians are living longer largely due to a remarkable trend that appeared about 40 years ago.
Medications
Aug 29, 2011 |
4.7 / 5 (3) |
0
Review: Blood pressure drug effective for treating PTSD-related nightmares
Mayo Clinic researchers this week will announce the use of the blood pressure drug prazosin as an effective treatment to curb post- traumatic stress disorder (PTSD)-related nightmares.
Psychology & Psychiatry
Mar 06, 2012 |
5 / 5 (2) |
0
NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular dea
An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is ...
Cardiology
Aug 22, 2012 |
5 / 5 (2) |
1
Triple mix of blood pressure drugs and painkillers linked to kidney problems
Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published in BMJ today.
Diseases, Conditions, Syndromes
Jan 08, 2013 |
5 / 5 (2) |
0
FDA approves 3 new drugs for type 2 diabetes
(HealthDay)—The U.S. Food and Drug Administration late Friday approved three new medications to help people battle type 2 diabetes.
Medications
Jan 26, 2013 |
5 / 5 (2) |
1
FDA warns consumers of dangers of the stimulant DMAA
(HealthDay)—The U.S. Food and Drug Administration is attempting to halt distribution of dietary supplements that contain the stimulant dimethylamylamine (DMAA), following reports of illness and death associated ...
Health
Apr 15, 2013 |
5 / 5 (2) |
0
Cholesterol-lowering statin drugs can reduce the risk of stroke, but sometimes should be avoided
For many patients, cholesterol-lowering statin drugs can reduce the risk of strokes as well as heart attacks. But in a review article, Loyola University Health System neurologists caution that statins may not be appropriate ...
Medications
Aug 19, 2011 |
5 / 5 (1) |
0
Diet and supplements: What's good and bad for kidney disease patients
Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on dietary benefits and dangers in kidney disease patients.
Diseases, Conditions, Syndromes
Nov 11, 2011 |
5 / 5 (1) |
1
No increased risk of serious cardiovascular events among adults who use ADHD medications: study
Although there have been cardiovascular safety concerns about attention-deficit/hyperactivity disorder (ADHD) medications because of their ability to increase heart rate and blood pressure levels, an analysis that included ...
Attention deficit disorders
Dec 12, 2011 |
5 / 5 (1) |
0
|
EU approves Novartis drug Signifor for Cushing's disease
European Union regulators have given Swiss pharmaceutical group Novartis a green light to market its drug Signifor as a treatment for Cushing's disease, the company said Wednesday.
Medications
Apr 25, 2012 |
5 / 5 (1) |
0
